ATX Ann: AMP945 Improves Survival in Human Pancreatic Cancer Model - 17th Feb 2022, 8:07am

zeeb0t

zeeb0t

Administrator
Staff member
ATX Ann: AMP945 Improves Survival in Human Pancreatic Cancer Model
Price Sensitive: Y
Date: 17th Feb 2022, 8:07am

>>> Read announcement: Google: ATX Market Announcements
 
  • Like
Reactions: 1 users
You must log in or register to reply here.

Similar threads

annb0t
ATX Ann: AMP945 International Nonproprietary Name Narmafotinib - 21st Jun 2023, 8:34am
Replies
0
Views
92
annb0t
annb0t
annb0t
ATX Ann: AMP945 and FOLFIRINOX active in model of Pancreatic Cancer - 29th May 2023, 8:42am
Replies
0
Views
101
annb0t
annb0t
annb0t
ATX Ann: Dose Escalation Approved in ACCENT Clinical Trial of AMP945 - 11th Apr 2023, 12:17pm
Replies
0
Views
144
annb0t
annb0t
annb0t
ATX Ann: Dose Escalation Approved in ACCENT Clinical Trial of AMP945 - 11th Jan 2023, 1:50pm
Replies
0
Views
158
annb0t
annb0t
annb0t
ATX Ann: AMP945 Shows Efficacy in Model of Lung Fibrosis - 2nd Jun 2022, 8:17am
Replies
0
Views
210
annb0t
annb0t
Top Bottom